Biotech firm Vectura has secured planning approval from the South Gloucestershire Council for the construction of a £58m research and development (R&D) facility in Bristol, UK.

Vectura specialises in asthma inhalers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The planned 10,000m² Inhalation Centre of Excellence will be constructed at Bristol & Bath Science Park in south-west England.

The Chippenham-based asthma inhaler producer is understood to have lined up Willmott Dixon for the construction of the facility, reported Construction Enquirer.

Construction of the facility is anticipated to complete in 2025.

See Also:

Vectura CEO Michael Austwick said: “The new-build will enable our already successful pharmaceutical company to continue and expand upon its vital work, providing innovative inhalation and other advanced drug delivery solutions that have the potential to improve the lives of patients around the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“For nearly 25 years, Vectura has been providing a combination of formulation science, device technology and pharmaceutical development expertise, helping our partners and licensees develop products which are used by 10 million patients worldwide. This new facility will help us to build on this successful track record, increasing workspace capacity and attracting talent to the area.”

The facility aims to achieve ‘Excellent’ rating with BREEAM.

In September 2021, Vectura was acquired in a £1bn deal by tobacco major Philip Morris.

—————————————————————————————————————-

Credit: Illustration of Inhalation Centre of Excellence. Credit: Vectura.